Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.35
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

6 Jul 2020 07:00

RNS Number : 0577S
ValiRx PLC
06 July 2020
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

CORPORATE UPDATE

 

London, UK, 06 July 2020: ValiRx (AIM:VAL) announces the launch of the new corporate strategy and its newly updated corporate website - www.valirx.com

 

ValiRx intends to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health. The Company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development.

 

It is intended that new projects will be held in newly formed subsidiaries ("Special Purpose Vehicles" or "SPVs") with the Company seeking external funding from partners to progress development towards clinical trials. ValiRx will provide the SPVs with corporate and project management support, being reimbursed accordingly. In the longer term, it is the objective that the incubation of early stage drug discovery projects become self-sustaining, with income from SPVs being used to support the working capital requirement of ValiRx and provide investment funding for further in-licensing.

 

Dr Suzy Dilly, Chief Executive Officer commented "We've shifted the development paradigm for ValiRx to earlier in the drug discovery process. This is intended to maximise the impact that our intellectual and financial contribution can make. With flexibility of thinking, small biotechnology incubator companies, supported by ValiRx, are ideally placed to perform the innovative early stage development work, and, rather than carrying out costly, time-consuming clinical trials ourselves, we will seek to have project partners prior to clinical testing.

 

We believe this strategy to be appropriate in the current financial and scientific environment, and invite academics, other biotechnology companies with early stage projects and any other innovators to present their early stage drug discovery projects to us for consideration."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

Tel: +44 (0) 20 7469 0930

 

 

Notes for Editors

 

About ValiRx

 

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDDBGDRSSGDGGU
Date   Source Headline
8th Sep 20204:04 pmRNSHolding(s) in Company
7th Sep 20201:30 pmRNSExercise of Warrant
7th Sep 20207:00 amRNSHalf-year Report
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSExercise of Warrants
20th Aug 202012:45 pmRNSHolding(s) in Company
19th Aug 20207:00 amRNSBlock Listing Application and Company Update
18th Aug 20207:00 amRNSHolding(s) in Company
14th Aug 20203:57 pmRNSHolding(s) in Company
10th Aug 20203:05 pmRNSHolding(s) in Company
7th Aug 20202:20 pmRNSDirector/PDMR Shareholding
5th Aug 20203:14 pmRNSHolding(s) in Company
3rd Aug 20202:49 pmRNSHolding(s) in Company
30th Jul 202011:05 amRNSSecond Price Monitoring Extn
30th Jul 202011:00 amRNSPrice Monitoring Extension
24th Jul 202012:38 pmRNSBroker Option - Fully Subscribed
23rd Jul 20204:41 pmRNSSecond Price Monitoring Extn
23rd Jul 20204:36 pmRNSPrice Monitoring Extension
23rd Jul 20203:02 pmRNSFundraise
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 20209:14 amRNSAGM Arrangements
6th Jul 20207:00 amRNSCorporate Update
1st Jul 20207:00 amRNSNotice of AGM
1st Jul 20207:00 amRNSFinal Results
29th Jun 202011:44 amRNSAppointment of Director
24th Jun 20201:24 pmRNSHolding(s) in Company
23rd Jun 20205:26 pmRNSHolding(s) in Company
22nd Jun 20202:06 pmRNSSecond Price Monitoring Extn
22nd Jun 20202:00 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSCorporate Update
11th Jun 20207:00 amRNSNew shareholder communication process
8th Jun 202011:08 amRNSCorrection Directorate Change & Audited accounts
8th Jun 20207:00 amRNSDirectorate Change & Audited accounts extension
2nd Jun 20209:56 amRNSHolding(s) in Company
2nd Jun 20209:05 amRNSSecond Price Monitoring Extn
2nd Jun 20209:00 amRNSPrice Monitoring Extension
2nd Jun 20207:41 amRNSCollaboration Agreement Signed
29th May 20207:00 amRNSPatent Assignment
27th May 20201:34 pmRNSHolding(s) in Company
27th May 20209:57 amRNSProposed Board Change
27th May 20208:54 amRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
22nd May 202012:04 pmRNSResult of General Meeting
19th May 20202:00 pmRNSGroup Projects Summary & Board Expansion Plans
7th May 20202:05 pmRNSSecond Price Monitoring Extn
7th May 20202:01 pmRNSPrice Monitoring Extension
7th May 20207:00 amRNSAppointment of Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.